Development and in-Vitro Evaluation of Raltegravir Sustain Release Tablets

Abstract

The present study focuses on the development and in-vitro evaluation of sustained release tablets of Raltegravir, an antiretroviral drug used in the treatment of HIV. The aim was to enhance therapeutic efficacy and patient compliance by reducing the frequency of drug administration through sustained drug release. Various formulations were prepared using different polymers, among which Karya gum was selected as the natural polymer for sustained release.

A total of several batches was formulated, and formulation R4, containing 100 mg of Karya gum, was found to be the optimized batch based on evaluation parameters. All pre-compression and post-compression parameters, including hardness, friability, weight variation, and drug content, were within acceptable limits. In-vitro dissolution studies revealed that formulation R4 exhibited a sustained drug release of 99.57% over a period of 12 hours.

The drug release kinetics of the optimized formulation followed a sustained release pattern, indicating its potential in maintaining consistent plasma levels and improving therapeutic outcomes. Hence, R4 formulation using Karya gum can be considered a promising sustained release system for Raltegravir.